Recombinant Human PD-L1/B7-H1 Fc Chimera Avi-tag Protein, CF
Recombinant Human PD-L1/B7-H1 Fc Chimera Avi-tag Protein, CF Summary
Why choose R&D Systems Avi-tag PD-L1 Protein?
- Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 90%.
- Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
- Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
- Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.
Find the His Avi-tag PD-L1 protein here His Avi-tag PD-L1 Protein
Find the full range of Avi-tag and amine biotinylated proteins Avi-tag Proteins
Accession # Q9NZQ7-1
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) is coated at 1 µg/mL, Biotinylated Recombinant Human PD-L1/B7-H1 Fc Chimera Avi-tag (Catalog # AVI156) binds with an ED50 of 8-48 ng/mL.
2 μg/lane of Biotinylated Recombinant Human PD-L1 Fc Chimera Avi-tag (Catalog # AVI156) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 70-80 kDa and 140-160 kDa, respectively.
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).
- Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
- Dong, H. et al. (1999) Nat. Med. 5:1365.
- Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
- Tamura, H. et al. (2001) Blood 97:1809.
- Chen, L. et al. (2007) J. Immunol. 178:6634.
- Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
- Tsushima, F. et al. (2007) Blood 110:180.
- Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
- Cao, Y. et al. (2010) Cancer Res. 71:1235.
- Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
- Dong, H. et al. (2002) Nat. Med. 8:793.
- Azuma, T. et al. (2008) Blood 111:3635.
- Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
- Park, J.-J. et al. (2010) Blood 116:1291.
- Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
- Herold, M. et al. (2015) J. Immunol. 195:3584.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Supplemental Cell Selection Products
Supplemental ELISA Products
Reviews for Recombinant Human PD-L1/B7-H1 Fc Chimera Avi-tag Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human PD-L1/B7-H1 Fc Chimera Avi-tag Protein, CF and earn rewards!
Have you used Recombinant Human PD-L1/B7-H1 Fc Chimera Avi-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image